Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer

NCT07379918 · clinicaltrials.gov ↗

RECRUITING

Status

1000

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer (Early Breast Cancer)
Breast Cancer Survivors
Breast Cancer Prognostic
Early Hormone Receptor-positive (HR-positive)
HER2-negative Breast Cancer

Interventions

OTHER: Endopredict test

Sponsor

Assistance Publique - Hôpitaux de Paris